You are here

Τσελέπης Αλέξανδρος

Τσελέπης Αλέξανδρος

Kαθηγητής Bιοχημείας - Κλινικής Χημείας

E-mail: atselep@uoi.gr

Tηλ: (+30) 26510-08365

Fax: (+30) 26510-08785

Διεύθυνση: Τμήμα Χημείας, Πανεπιστημιούπολη Δουρούτης, 45110 Iωάννινα

Ιστοσελίδα: Ερευνητικό Κέντρο Αθηροθρόμβωσης (http://atherothrombosis.lab.uoi.gr)

 

Σπουδές

1974-1979: Πτυχίο Φαρμακευτικού Tμήματος Παν/μίου Θεσ/νίκης.

1983-1991: Πτυχίο Iατρικής Σχολής Παν/μίου Iωαννίνων.

1980-1986: Διδακτορικό Δίπλωμα Tμήματος Xημείας Παν/μίου Iωαννίνων.

 

Eπιστημονική και επαγγελματική εξέλιξη

1980-1986: Eπιστημονικός Συνεργάτης Bιοχημείας, Tμήματος Xημείας Παν/μίου Iωαννίνων.

1987-1992: Λέκτορας Bιοχημείας, Tμήματος Xημείας Παν/μίου Iωαννίνων.

1988-1989: Mεταδιδακτορικός Ερευνητής, με υποτροφία Fogarty (NIH), στο Pathology Department, University of Texas Health Science Center at San Antonio, Texas, USA.

1992-2000: Eπίκουρος Kαθηγητής Bιοχημείας-Κλινικής Χημείας, Tμήματος Xημείας Παν/μίουIωαννίνων.

1994-1999:     Προσκεκλημένος ερευνητής στο INSERM U321, Παρίσι (3 μήνες ετησίως).

2000-2006: Aναπληρωτής Kαθηγητής Bιοχημείας-Κλινικής Χημείας, Tμήματος Xημείας Παν/μίου Iωαννίνων.

2006-Σήμερα: Καθηγητής Bιοχημείας-Κλινικής Χημείας, Tμήματος Xημείας Παν/μίου Iωαννίνων.

2012-Σήμερα: Πρόεδρος της Επιστημονικής Επιτροπής και Επιστιμονικώς Υπεύθυνος του Ερευνητικού Κέντρου Αθηροθρόμβωσης του Δικτύου Εργαστηρίων Υποστήριξης Έρευνας του Παν/μίου Ιωαννίνων (http://atherothrombosis.lab.uoi.gr).

 

Yποτροφίες

1. Yποτροφία Fogarty (National Institutes of Health USA, NIH), από 1-9-1988 έως 31-12-1989, για μεταδιδακτορική έρευνα στο Health Science Center (Pathology Department), San Antonio Texas, USA.

2. Yποτροφία της Γαλλικής Πρεσβείας από 1-8-1996 έως 31-10-1996. Χρησιμοποίησα την υποτροφία εργαζόμενος ερευνητικά στο INSERM U 321 στο Παρίσι.

 

Mέλος επιστημονικών συλλόγων-εταιρειών

1. International Society on Thrombosis and Haemostasis

2. Mediterranean League Against Thromboembolic Diseases

3. European Atherosclerosis Society

4. European Atherosclerosis Club

5. Ελληνική Εταιρεία Αθηροσκλήρωσης. Πρόεδρος για τα έτη 2014-2016

6. Ινστιτούτο Μελέτης και Εκπαίδευσης στη Θρόμβωση και την Αντιθρομβωτική Αγωγή. Πρόεδρος για τα έτη 2012-2014

7. Eλληνική Eταιρεία Λιπιδιολογίας και Αθηροσκλήρωσης

8. Eλληνική Eταιρεία Bιοχημείας και Mοριακής Bιολογίας

9. Eλληνική Eταιρεία Kλινικής Xημείας-Kλινικής Bιοχημείας

10. Ελληνική Εταιρεία Ελευθέρων Ριζών και Οξειδωτικού Στρες. Διετέλεσα Πρόεδρος για τα έτη 2004-2008

11. Iατρικός Σύλλογος Iωαννίνων

12. Πανελλήνια Ένωση Φαρμακοποιών

 

Συμμετοχή σε Συντακτικές Επιτροπές Περιοδικών

  1. Διευθυντής Σύνταξης του Περιοδικού “Ελληνική Επιθεώρηση Αθηροσκλήρωσης”, Επίσημης Έκδοσης της Ελληνικής Εταιρείας Αθηροσκλήρωσης
  2. Μέλος Συντακτικών Επιτροπών των Παρακάτω Περιοδικών:
  • Vascular Disease Prevention (Section Editor in Vascular and Cellular Clinical Biochemistry)
  • American Journal of Biochemistry and Biotechnology
  • Platelets
  • Journal of Cardiology and Therapy

 

Διοικητικό έργο

  1. Διευθυντής και Μέλος της Συντονιστικής Επιτροπής του Προγράμματος Μεταπτυχιακών Σπουδών του Τμήματος Χημείας
  2. Μέλος της Επιτροπής Προπτυχιακού Προγράμματος Σπουδών
  3. Mέλος της ΓΣ του Tομέα Oργανικής Xημείας και Bιοχημείας από το 1987 έως σήμερα και  Διευθυντής του Tομέα τα ακαδημαϊκά έτη 2002-03 και 2003-04.
  4. Mέλος της ΓΣ του Tμήματος Xημείας από το 1987 έως σήμερα.
  5. Μέλος της Εκτελεστικής Επιτροπής του Μιχαηλίδειου Καρδιολογικού Κέντρου του Παν/μίου Ιωαννίνων.
  6. Τακτικό Mέλος της Ολομέλειας της Επιτροπής Ερευνών του Παν/μίου Ιωαννίνων (2008-2011) και Αναπληρωματικό Μέλος (2011-2014).

 

Διδασκαλία

Προπτυχιακά μαθήματα

Eργαστήριο Bιοχημείας, Kλινική Χημεία, Eργαστήριο Kλινικής Χημείας, Φυσιολογία του Ανθρώπου

Μεταπτυχιακά μαθήματα

Βιοχημεία, Εργαστήριο Βιοχημείας, Κλινική Βιοχημεία, Εργαστήριο Κλινικής Βιοχημείας, Βιοχημεία της Φλεγμονής, Βιοχημική Φυσιολογία Ανθρώπου

Επίβλεψη Διδακτορικών Διατριβών και ΜΔΕ

Έχω επιβλέψει 13 Διδακτορικές Διατριβές και 21 ΜΔΕ, ενώ έχω συμμετάσχει σε περισσότερες από 90 3/μελείς Συμβουλευτικές και 7/μελείς Εξεταστικές Επιτροπές Διδακτορικών Διατριβών, καθώς και σε 3/μελείς Εξεταστικές Επιτροπές ΜΔΕ.

 

Συγγραφή Βιβλίων - Εκπαιδευτικών Βοηθημάτων

  1. Bioactive Phospholipids. Role in Inflammation and Atherosclerosis. AD Tselepis Editor, Tranworld Research Network 2008.
  2. Κατευθυντήριες Οδηγίες για την Αντιαιμοπεταλιακή Αγωγή στην Πρωτογενή και Δευτερογενή Πρόληψη της Καρδιαγγειακής Νόσου. Ελλ. Καρδιολ. Επιθ. 2012; 53 (Συμπλήρωμα Β): 1-56. Συντονιστής της Επιτροπής Συγγραφής των Οδηγιών και Υπέυθυνος για την αλληλογραφία.
  3.  Θέματα Kλινικής Xημείας. Tσελέπη AΔ, Tσουκάτου ΔK. Tμήμα Xημείας Παν/μιο Iωαννίνων, Iωάννινα 1997.
  4. Στοιχεία Φυσιολογίας του Aνθρώπου. Tσελέπη AΔ, Tσουκάτου ΔK. Tμήμα Xημείας Παν/μιο Iωαννίνων, Iωάννινα 1997.
  5. Eργαστηριακές Aσκήσεις Kλινικής Xημείας. Tσουκάτου ΔK, Tσελέπη AΔ. Tμήμα Xημείας Παν/μιο Iωαννίνων, Iωάννινα 1998.
  6. Eργαστηριακές Aσκήσεις Bιοχημείας. E. Πάνου, A. Περισυνάκη, A. Kούκκου, E.Παπαμιχαήλ, M. Λέκκα, Δ. Tσουκάτου, A. Tσελέπη, K. Δραΐνα, M. Σακαρέλλου-Δαϊτσιώτου. Tμήμα Xημείας Παν/μιο Iωαννίνων, Iωάννινα 1998.
  7. Aγγλοελληνικό Λεξικό Bιοχημείας Mοριακής Bιολογίας και Bιοτεχνολογίας. Ελληνική Εταιρεία Βιοχημείας και Μοριακής Βιολογίας - Eλληνική Eταιρεία Βιοτεχνολογίας. K.Δραΐνα, Φ. Kολίση, M. Λέκκα, Γ. Παλαιολόγου, Δ. Σταθάκου, A. Tσελέπη, K. Tσίγγανου. Iωάννινα 1995. Σήμερα είναι σε εξέλιξη προσπάθεια για την επανέκδοση του λεξικού εμπλουτισμένου με νέους όρους.
  8. Πρωτεΐνες: Απομόνωση-Καθαρισμός-Ανίχνευση. Τσελέπη Α, Τέλλη Κ. Συμπληρωματικές σημειώσεις ΙΙ μεταπτυχιακών μαθημάτων Βιοανόργανης Χημείας. (Υπεύθ. Ν. Χατζηλιάδης), Ιωάννινα 2002, σελ. 263-304.
  9. Τσελέπης ΑΔ. Δομή και μεταβολισμός των λιποπρωτεϊνών. Λιπίδια-Λιποπρωτεΐνες, 5ο Εκπαιδευτικό σεμινάριο, Ελληνική Εταιρία Κλινικής Χημείας-Κλινικής Βιοχημείας, Αθήνα 2004, σελ. 18-34.
  10. Τσελέπης Α, Ταμπάκη Α. Ένζυμα και Πρωτεΐνες Μεταφοράς Λιπιδίων - Ο Ρόλος στο Μεταβολισμό των Λιποπρωτεϊνών και στην Αθηροσκλήρωση. «Τα λιπίδια στην κλινική πράξη». Γ. Κολοβού, Δ. Κόκκινος. Αθήνα 2005, σελ. 71-94.

 

Ερευνητικά Ενδιαφέροντα

Τα ερευνητικά ενδιαφέροντα εστιάζονται τόσο σε βασική όσο και σε κλινική έρευνα και αφορούν στην παθοφυσιολογία της Αθηροθρόμβωσης και ιδιαίτερα στο ρόλο των λιποπρωτεϊνών και των αιμοπεταλίων στην ανάπτυξη της αθηρωματικής πλάκας, στις θρομβωτικές επιπλοκές της ρήξης της πλάκας καθώς και στους μηχανισμούς αναγέννησης του αγγειακού ενδοθηλίου. Οι ερευνητικές δραστηριότητες τα τελευταία χρόνια έχουν επικεντρωθεί στα παρακάτω θέματα:

  1. Διερεύνηση του ρόλου τον αιμοπεταλίων στην αγγειακή φλεγμονή και την αναγέννηση του αγγειακού ενδοθηλίου. Στα πλαίσια αυτά διερευνώνται οι μηχανισμοί αλληλεπίδρασης αιμοπεταλίων με ενδοθηλιακά κύτταρα, λευκοκύτταρα και κυκλοφορούντα πρόδρομα CD34+ κύτταρα, η έκκριση αντι- και προ- αγγειογενετικών παραγόντων, η ενεργοποίηση και ο ρόλος των υποδοχέων PAR-1 και PAR-4, κλπ.
  2. Μελέτη τη επίδρασης αντιαιμοπεταλιακών φαρμάκων στη λειτουργικότητα των αιμοπεταλίων σε ασθενείς με καρδιαγγειακή νόσο.
  3. Μελέτη του ρόλου της λιποπρωτεϊνικής φωσφολιπάσης A2 (Lp-PLA2) στην αθηρογένεση.
  4. Επίδραση κλασικών και νεώτερων υπολιπιδαιμικών φαρμάκων στο φαινότυπο και τη λειτουργικότητα των λιποπρωτεϊνικών σωματιδίων με έμφαση στα αθηρογόνα μικρά-πυκνά (sdLDL) σωματίδια, στην Lp(a) και στην HDL, σε ασθενείς με δυσλιπιδαιμίες.
  5. Ενζυμική τροποποίηση ουσιών φυσικής προέλευσης με αντιαθηρογόνες και αντιθρομβωτικές δράσεις με σκοπό τη βελτίωση της βιολογικής τους δραστικότητας.

Για τη σύγχρονη και  ολοκληρωμένη  διερεύνηση των παραπάνω θεμάτων έχει αναπτυχθεί σύγχρονη μεθοδολογία καθώς και η απαιτούμενη εργαστηριακή υποδομή. Η μεθοδολογία περιλαμβάνει μεταξύ των άλλων και τις παρακάτω τεχνικές:

  1. Μέθοδοι μελέτης της λειτουργικότητας των αιμοπεταλίων και των μηχανισμών πήξης (παρασκευή και συσσώρευση αιμοπεταλίων σε διάφορους αγωνιστές, έλεγχος της αντίστασης στα αντιαιμοπεταλιακά φάρμακα, μελέτη της μεμβρανικής έκφρασης διαφόρων υποδοχέων και προσδετών με κυτταρομετρία ροής, παραγωγή, καθαρισμός και χαρακτηρισμός των αιμοπεταλιακών μικροσωματιδίων; PMPs, μελέτη της προσκόλλησης των αιμοπεταλίων υπό συνθήκες ροής με την πλατφόρμα Cellix, προσδιορισμός της έκκρισης αιμοπεταλιακών παραγόντων προσδιορισμός της έκκρισης αιμοπεταλιακών παραγόντων, προσδιορισμός κλασσικών παραμέτρων πήξης καθώς και της αντιπηκτικής αποτελεσματικότητας των νέων από του στόματος αναστολέων του Xa και της θρομβίνης).
  2. Μέθοδοι μελέτης της λειτουργικότητας των λιποπρωτεϊνικών σωματιδίων (διαχωρισμός και απομόνωση λιποπρωτεϊνών VLDL, LDL, HDL, Lp(a) καθώς και των υποκλασμάτων τους,  προσδιορισμός των επιπέδων της preβ1-HDL, παρασκευή και μελέτη των βιολογικλών δρλασεων της οξειδωμλενης LDL; oxLDL, προσδιορισμός της ενεργότητας και της μάζας της λιποπρωτεϊνικής φωσφολιπάσης A2; Lp-PLA2, καθώς και των ενζύμων και πρωτεϊνών μεταφοράς  LPL, CETP HL, LCAT, μελέτη των αντιαθηρογόνων δράσεων της HDL, αντιοξειδωτική δράση,  εκροής χοληστερόλης από μακροφάγα που υπερεκφράζουν τους υποδοχείς ABCA1, ABCG1 ή SRB1, προσδιορισμός των ενεργοτήτων των ενζύμων που συνδέονται στην HDL, PON-1, LCAT, Lp-PLA2).
  3. Μέθοδοι μελέτης του οξειδωτικού στρες (προσδιορισμός των επιπέδων της oxLDL, των αντισωμάτων έναντι της oxLDL στον ορό, προσδιορισμός δεικτών οξειδωτικού stress όπως 8-ισοπροστάνια; 8-epiPGF2a, καρβονύλια πρωτεϊνών, 3-νιτροτυροσίνη, 8-υδροξυγουανοσίνη, κλπ).

Οι παραπάνω ερευνητικές δραστηριότητες διεξάγονται κυρίως στο Ερευνητικό Κέντρο Αθηροθρόμβωσης (EKA), μια προηγμένη και σύγχρονη εργαστηριακή μονάδα η οποία εστιάζεται στην έρευνα για την Αθηροθρόμβωση. Περισσότερα για το ΕΚΑ υπάρχουν στην ιστοσελίδα http://atherothrombosis.lab.uoi.gr.

 

Χρηματοδοτήσεις προγραμμάτων

Eπιτρ. Eρευν. Παν/μίου Iωαννίνων 1988, ΠENEΔ 1991 EΔ 369 ΓΓET, ΠENEΔ 1991 EΔ 927ΓΓET, BIOMED 2 BMH4-CT98-3191 EU, KEΣY 1992 E326 Yπουργείο Yγείας, STRIDE Hellas-33 1992 ΓΓET, YΠEP 1994 EΔ 343 ΓΓET, ΠENEΔ 1994 EΔ 656 ΓΓET, EPET II 97 EKBAN 2-25ΓΓET, EΠET II 97 ΔIATPO-25 ΓΓET, Eπιτρ. Eρευν. Παν/μίου Iωαννίνων 1999, ΠΑΒΕΤ 2000ΓΓΕΤ, Πρόγραμμα Επιστημονικής και Τεχνολογικής Συνεργασίας Ελλάδας-Κϋπρου 2001ΓΓΕΤ, ΠΕΝΕΔ 2001 ΕΔ375 ΓΓΕΤ, ΕΠΑΝ Υγεία-Βιοϊατρική ΣΠ-ΥΒ88 2003 ΓΓΕΤ, ΗΡΑΚΛΕΙΤΟΣ 2003 ΥΠΕΠΘ, ΠENEΔ 2003 03ΕΔ643 ΓΓET, ΠΥΘΑΓΟΡΑΣ Ι 2004 ΥΠΕΠΘ, FEBS special Meeting 45th ICBL 2004 (FEBS Special Meeting 04-09M), IUBMB sponsorship for the 45th ICBL 2004, ΠΥΘΑΓΟΡΑΣ ΙΙ 2005 ΥΠΕΠΘ, ΣΥΝΕΡΓΑΣΙΑ 2009 (09ΣΥΝ-827) Υπουργείο Παιδείας, Δια Βίου Μάθησης και Θρησκευμάτων.

 

Αναφορές – h index

Σύνολο αναφορών (αριθμός): 4.200,  h Index: 33

 

Δημοσιεύσεις σε Διεθνή Περιοδικά

  1. Tselepis A, Tsoukatos D, Demopoulos CA, Kapoulas VM. Effects of AGEPC on the intracellular levels of ions in Tetrahymena pyriformis. Biochem Intern. 1986; 13: 999-1008.
  2. Lekka M, Tselepis AD, Tsoukatos D. 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) is a minor lipid component in Tetrahymena pyriformis cells. FEBS Lett. 1986; 208: 52-55.
  3. Tselepis AD, Evangelou A, Tsoukatos D, Demopoulos CA, Kapoulas VM. Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. Comp Biochem Physiol. 1987; 87C: 41-46.
  4. Lekka ME, Tsoukatos DC, Tselepis AD, Kapoulas VM. Semisynthetic preparation of 1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (Platelet Activating Factor). Z Naturforsch. 1988; 43C: 665-670.
  5. Tselepis AD, Tsoukatos D, Evangelou A, Donos A, Droudes C. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction. Eur J Clin Invest. 1991; 21: 490-496.
  6. Tselepis AD, Lekka ME, Tsoukatos D. A PAF-acetylhydrolase activity in Tetrahymena pyriformis cells. FEBS Lett. 1991; 288: 147-150.
  7. Tselepis AD, Pinckard, R.N. PAF-acetylhydrolase: A novel enzyme with biochemical and clinical interest. Clin Chem Enzymol Commun. 1992; 4: 279-290.
  8. Tsoukatos D, Tselepis AD, Lekka ME. Studies on the subcellular distribution of 1-O-alkyl-2-acetyl-sn-glycerophosphocholine (PAF) and on the enzymic activities involved in its biosynthesis within the ciliate Tetrahymena pyriformis. Biochim Biophys Acta. 1993; 1170: 258-264.
  9. Tsoukatos D, Demopoulos CA, Tselepis AD, Moschidis M, Donos A, Evangelou A, Benveniste J. Inhibition by cardiolipins of paf induced rabbit platelet activation. Lipids. 1993; 28: 1119-1125.
  10. Liapikos ThA, Antonopoulou S, Karabina S-AP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta. 1994; 1212: 353-360.
  11. Karabina S-AP, Liapikos, ThA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low density lipoprotein subfractions. Biochim Biophys Acta. 1994; 1213: 34-38.
  12. Goudevenos J, Tselepis AD, Tsoukatos D, Grekas G, Kritikakos J, Sideris D. Platelet aggregability to platelet activating factor (PAF) at rest and after exercise in patients with coronary artery disease. Eur Heart J. 1995; 16: 1036-1043.
  13. Tselepis AD, Dentan C, Karabina S-AP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995; 15: 1764-1773.
  14. Dentan C, Tselepis AD, Chapman MJ, Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible infibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta. 1996; 1299: 353-357.
  15. Karabina S-AP, Elisaf MC, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis AD. PAF-acetylhydrolase activity on Lp(a) before and during Cu2+-induced oxidative modification in vitro. Atherosclerosis. 1996; 125: 121-134.
  16. Tselepis AD, Elisaf M, Goudevenos J, Tselegaridis T, Bairaktari E, Siamopoulos KC, Sideris D. Lipid profile in patients with microvascular angina. Eur J Clin Invest. 1996; 26: 1150-1155.
  17. Elisaf MS, Siamopoulos KC, Tselegarides TJ, Bairaktari ET, Goudevenos JA, Tselepis AD, Tsolas OE, Sideris DA. Lipid abnormalities in Greek patients with coronary artery disease. Int J Cardiol. 1997; 59: 177-184.
  18. Karabina S-AP, Elisaf MC, Bairaktari E, Tziallas C, Siamopoulos KC, Tselepis AD. Increased activity of PAF-acetylhydrolase in low density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest. 1997; 27: 595-602.
  19. Tselepis AD, Karabina S-AP, Elisaf M. PAF-acetylhydrolase activity in familial hypercholesterolaemia. Eur J Clin Invest. 1998; 28: 508-509 (Letter).
  20. Elisaf MS, Karabina S-AP, Tselepis AD. High density lipoprotein changes in patients with microvascular angina. Cardiovasc Res. 1998; 40: 418 (Letter).
  21. Theodoraki TG, Tsoukatos DC, Tselepis AD, Rallides L, Papageorgakis NH, Anagnostou ED, Joullien GL. HDL-subclasses and other lipid parameters in patients with old myocardial infarction. Clin Chem Enzymol Commun. 1999; 8: 175-187.
  22. Tselepis AD, Elisaf M, Besis S, Karabina S-AP, Chapman MJ, Siamopoulou A. The inflammatory state in active juvenile chronic arthritis is associated with hypo HDL-emia and reduced lipoprotein-associated PAF-acetylhydrolase activity. Arthritis Rheum. 1999; 42: 373-383.
  23. Elisaf M, Karabina S-AP, Bairaktari E, Goudevenos JA, Siamopoulos KC, Tselepis AD. Increased platelet reactivity to the aggregatory effect of platelet activating factor (PAF) in vitro in patients with heterozygous familial hypercholesterolaemia. Platelets. 1999; 10: 124-131.
  24. Bairaktari ET, Tselepis AD, Millionis HJ, Elisaf MS. Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunity. Eur J Endocrinol. 1999; 140: 474-476.
  25. Milionis HJ, Elisaf MS, Tselepis AD, Bairaktari E, Karabina S-AP, Siamopoulos KC. Apolipoprotein (a) phenotypes and lipoprotein (a) concentrations in patients with renal failure. Am J Kidney Dis. 1999; 33: 1100-1106.
  26. Elisaf M, Tselepis A, Siamopoulos K. Selective imidazoline receptor agonists and lipid metabolism. Clin Chem Lab Med. 1999; 37: 165 (Letter).
  27. Tselepis AD, Goudevenos JA, Tambaki AP, Michalis L, Stroumbis CS, Tsoukatos DC, Elisaf M, Sideris D. Platelet aggregatory response to platelet activating factor (PAF) ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina. Effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res. 1999; 43: 183-191.
  28. Bairaktari E, Elisaf M, Katsaraki A, Tsimihodimos V, Tselepis AD, Siamopoulos KC, Tsolas O. Homogeneous HDL-cholesterol assay versus ultracentrifugation /dextran sulfate-Mg2+ precipitation and dextran sulfate-Mg2+ precipitation in healthy population and in hemodialysis patients. Clin Biochem. 1999; 32: 339-346.
  29. Elisaf MS, Petris C, Bairaktari E, Karabina S-A, Tzallas C, Tselepis A, Siamopoulos KC. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Hum Hypertens. 1999; 13: 781-785.
  30. Milionis HJ, Elisaf MS, Karabina S-AP, Bairaktari E, Tselepis AD, Siamopoulos KC. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int. 1999; 56: 2276-2285.
  31. Theodoraki TG, Tsoukatos DC, Karabina S-A, Rallidis LS, Papageorgakis NH, Tselepis AD. LDL subfractions in patients with myocardial infarction. Effect of smoking and β-blocker treatment. Ann Clin Biochem. 2000; 37: 313-318.
  32. Goudevenos J, Tselepis AD, Vini MP, Michalis L, Tsoukatos DC, Elisaf M, Ninio E, Sideris DA. Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina. Sequential changes of the enzyme activity after angioplasty. Eur J Clin Invest. 2000; 31: 15-23.
  33. Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis AD, Elisaf M, Tsolas O. Estimation of LDL-cholesterol based on Friedewald formula and on apo B levels. Clin Biochem. 2000; 33: 549-555.
  34. Bairaktari ET, Milionis HJ, Katopodis K, Tzallas C, Tselepis AD, Tsolas O, Siamopoulos KC, Elisaf MS. Lipoprotein (a), apolipoprotein (a) phenotypes, and thyroid autoimmunity in uremic patients. The Endocrinologist. 2000; 10: 383-388.
  35. Tsoukatos DC, Liapikos TA, Tselepis AD, Chapman MJ, Ninio E. Enzymatic reactions catalyzing the transfer of acetate to lyso-platelet activating factor are involved in platelet activating factor formation on oxidized or acetylated low density lipoprotein. Biochem J. 2001; 357: 457-464.
  36. Tselepis A, Doulias P, Lourida E, Glatzounis G, Tsimoyiannis E, Galaris D. Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H2O2 from DNA damage. Free Rad Biol Med. 2001; 30: 1357-1364.
  37. Skrapari I, Perrea D, Ioannidis I, Karabina SA, Elisaf M, Tselepis AD, Karagiannacos P, Katsilambros N. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the VLDL subfraction levels. Diabet Med. 2001; 18: 781-785.
  38. Tselepis AD, Karabina S-AP, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res. 2001; 42: 1645-1654.
  39. Katsouras CS, Karabina SP, Tambaki AP, Goudevenos JA, Michalis LK, Tsironis LD, Stroumbis CS, Elisaf MS, Sideris DA, Tselepis AD. Serum lipoprotein (a) concentrations and lipoprotein (a) isoforms: association with the severity of clinical presentation in patients with coronary artery disease. J Cardiovasc Risk. 2001; 8: 311-317.
  40. Manataki AD, Tselepis AD, Glantzounis GK, Arnaoutoglou HM, Tsimoyiannis EC, Stavropoulos NE. Lipid peroxidation and the use of emulsified propofol in laparoscopic surgery. Surg Endosc. 2001;15: 950-953.
  41. Glantzounis GK, Tselepis AD, Tambaki AP, Trikalinos TA, Manataki AD, Galaris DA, Tsimoyiannis EC, Kappas AM. Laparoscopic surgery-induced changes in oxidative stress markers in human plasma. Surg Endosc. 2001; 15: 1315-1319.
  42. Bairaktari E, Elisaf M, Tzallas C, Karabina S-A, Tselepis AD, Siamopoulos KC, Tsolas O. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients. Clin Biochem. 2001; 34: 593-602.
  43. Goudevenos JA, Tselepis AD. Basic and clinical aspects of platelet integrin αIIbβ3 receptor antagonists in acute coronary syndromes. Curr Opinion Invest Drugs. 2001; 2: 244-249.
  44. Tsimihodimos V, Karabina S-AP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. Atorvastatin Preferentially Reduces LDL-Associated Platelet Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and IIB. Arterioscler Thromb Vasc Biol. 2002; 22: 306-311.
  45. Tsimihodimos V, Karabina S-AP, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002; 43: 256-263.
  46. Michalis LK, Tambaki A, Katsouras CS, Goudevenos JA, Kolettis T, Adamides K, Tselepis AD, Sideris DA. Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes. Curr Med Res Opinion. 2002; 18: 108-112.
  47. Liberopoulos E, Karabina SA, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, Elisaf M. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein e phenotypes? Oncology. 2002; 62: 115-120.
  48. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis (Suppl). 2002; 3: 57-68.
  49. Milionis HJ, Efstathiadou Z, Tselepis AD, Bairaktari ET, Tsironis LD, Tsatsoulis A, Elisaf MS. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroism: Effect of tretment with L-Thyroxine. Thyroid. 2003; 13:365-369.
  50. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003; 66: 2069-2073.
  51. Tentolouris N, Kolia M, Tselepis AD, Perea D, Kitsou E, Kyriaki D, Tambaki AP, Karabina SP, Sala C, Fragoulopoulos E, Katsilambros N. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. Exp Clin Endocr Diab. 2003; 111: 370-373.
  52. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD. Fenofibrate induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res. 2003; 44: 927-934.
  53. Tsimihodimos V, Karabina S-A, Tambaki A, Bairaktari E, Achimastos A, Tselepis A, Elisaf M. Εffect of atorvastatin on the concentration, relative distribution and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. J Cardiovasc Pharmacol. 2003; 42: 304-310.
  54. Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD. The PON-1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity in normolipidemic and dyslipidemic populations. J Lipid Res. 2003; 44: 1919-1926.
  55. Biris N, Abatzis M, Mitsios JV, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tselepis AD, Michalis L, Sideris D, Konidou G, Soteriadou K, Tsikaris V. Mapping the binding domains of the aIIb subunit: A study performed on the activated form of the platelet integrin aIIbb3. Eur J Biochem. 2003; 270: 3760-3767.
  56. Tselepis AD. Platelet activating factor acetylhydrolase in dyslipidemias. IAS E-NEWSLETTER-August 2003; http//www.athero.org (invited commentary).
  57. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003; 66: 2069-2073.
  58. Karabina SA, Pappas H, Militiadous G, Bairaktari E, Christides D, Tselepis AD, M Elisaf M, Siampoulos K. Compositional lipoprotein changes and LDL susceptibility to oxidation in chronic renal failure patients with heavy proteinuria. Nephron Clin Pract. 2003; 95: c77-c83.
  59. Mitsios JV, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M, Tsoukatos D, Tsikaris V, Tselepis AD. Effect of synthetic peptides corresponding to residues 313-332 of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3. Eur J Biochem. 2004; 271: 855-862.
  60. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel, when it is concomitantly administered for 5 weeks in patients with acute coronary syndromes. Circulation. 2004; 109:1335-1338.
  61. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of fenofibrate on serum inflammatory markers in patients with high triglycerides values. J Cardiov Pharm Therap. 2004; 9: 27-33.
  62. Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor (PAF): Role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiov Res. 2004; 63: 130-138.
  63. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodyalysis patients. Am J Kidney Dis. 2004; 44: 300-308.
  64. Balafa OCh, Karabina S-AP, Pappas CA, Elisaf MS, Tselepis AD, Siamopoulos KC. Urine of patients with nephrotic syndrome contain the plasma type of PAF-acetylhydrolase associated with lipoproteins. Nephron Physiol. 2004; 97: 45-52.
  65. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Clinical significance of the Atorvastatin–Clopidogrel drug–drug interaction • Response Circulation. 2004; 110: e66 - e67.
  66. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Potential Statin–Clopidogrel interaction requires more study • Response. Circulation. 2004; 110: e68.
  67. Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M. Effect of antihypertensive and hypolipidemic drugs on plasma and HDL-associated PAF-acetylhydrolase activity. J Cardiovasc Pharmacol Ther. 2004; 9: 91-95.
  68. Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, Elisaf MS. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004; 24: 580-589.
  69. Tsironis LD, Katsouras CS, Lourida E, Mitsios JV, Goudevenos JA, Elisaf M, Tselepis AD. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004; 177: 193-201.
  70. Tsimihodimos V, Elisaf M, Tselepis A, Tambaki A, Bairaktari E. Effect of fenofibrate on the concentration and relative distribution of LDL subfractions in patients with combined dyslipidemia. Letters in Drug Design and Discovery. In press
  71. Tentolouris N, Boutati E, Karambakalis N, Perea D, Tselepis AD, Tsoukala C, Kyriaki D, Lourida E, Anastasopoulou I, Karafoullidou A, Raptis SA, Katsilambros N. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis. Nutr Metab Cardiov Dis. 2005; 15: 6-12.
  72. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005; 72: 203-209.
  73. Mellou F, Lazari D, Skaltsa H, Tselepis AD, Kolisis FN, Stamatis H. Biocatalytic preparation of acylated derivatives of flavonoid glucosides enhances their antioxidant and antimicrobial activity. J Biotechnol. 2005; 116: 295-304.
  74. Tselepis AD, Lourida ES, Tzimas PC, Roussis IG. Comparative antioxidant effectiveness of white and red wine and their phenolic extracts towards low-density lipoprotein oxidation. Food Biotechnol. 2005; 19: 1-14.
  75. Milionis HJ, Tselepis AD, Tsatsoulis A, Elisaf MS. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism. 2005; 54: 559-560 (Letter).
  76. Tselepis AD, Goudevenos JA. Lipophilic statins do not affect the antiplatelet potency of clopidogrel. Platelets. 2005; 16: 225-226 (Letter).
  77. Glantzounis GK, Tsimaris I, Tselepis AD, Thomas C, Galaris DA, Tsimoyiannis EC. Alterations in plasma oxidative stress markers after laparoscopic operations of the upper and lower abdomen. Angiology. 2005; 56: 459-465.
  78. Milionis HJ, Tambaki A, Kanioglou C, Elisaf MS, Tselepis AD, Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: A potential antiatherogenic effect. Thyroid. 2005; 15: 455-460.
  79. Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology. 2005; 56: 451-458.
  80. Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets. 2005; 16: 287-292.
  81. Kouki Α, MitsiosJV, Sakarellos-Daitsiotis M, Sakarellos C, Tselepis AD, Tsikaris V, Tsoukatos DC. Highly constrained cyclic (S,S) –CXaaC- peptides as inhibitors of fibrinogen binding to platelets. J Thromb Haemost. 2005; 3: 2324-2330.
  82. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease. Effect of long term therapy with erythropoietin. Kidney Int. 2005; 68: 246-255.
  83. Katsouras CS, Tsironis LD, Moses Elisaf M, John A Goudevenos JA, Michalis LK, Tselepis AD. Lipoprotein(a) as a cardiovascular risk factor. Future Cardiol. 2005;1:1–9.
  84. Miltiadous G, Hatzivassiliou M, Liberopoulos E, Bairaktari E, Tselepis A, Cariolou M, Elisaf M. Gene polymorphisms affecting HDL-cholesterol levels in the normolipidemic population. Nutr Metab Cardiov Disease. 2005; 15: 219-224.
  85. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005; 51: 2264-2273.
  86. Milionis HJ, Filippatos TD, Tsironis L, Bairaktari ET, Tselepis AD, Elisaf MS Serum lipoprotein (a) levels and apolipoprotein (a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis. 2006; 187: 170-176.
  87. Mitsios JV, Stamos G, Rodis FI, Tsironis LD, Stanica M-R, Sakarellos C, Tsoukatos D, Tsikaris V, Tselepis AD. Investigation of the role of adjacent amino acids to the 313-320 sequence of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3. Platelets. 2006; 17:277-82.
  88. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transpl. 2006; 21: 1270-1277.
  89. Gazi I, Tsimihodimos V, Filippatos TD, Saougos VG, Bairaktari ET, Tselepis AD, Elisaf M. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis. 2006; 5:8.
  90. Liberopoulos EN, Elisaf MS, Tselepis AD, Archimandritis A, Kiskinis D, Cokkinos D, Mikhailidis DP. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now? Platelets. 2006; 17: 1–6.
  91. Tsouli SG, Kiortsis DN, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD. Antibodies against various forms of mildly oxidized LDL are not associated with carotid intima-media thickness in patients with primary hyperlipidemia. Angiology. 2006 ;57:615-22.
  92. Katsoura MH, Polydera AC, Tsironis L, Tselepis AD, Stamatis H. Use of ionic liquids as media for the biocatalytic preparation of flavonoid derivatives with antioxidant potency. J Biotechnol. 2006; 123: 491-503.
  93. Tsouli SG, Kiortsis DN, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD. Autoantibody titers against oxidized LDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J. Lipid Res. 2006; 47: 2208-14.
  94. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther. 2006;11:256-61.
  95. Mitsios JV, Vini MP, Stengel D, Ninio E, Tselepis AD. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol. 2006; 26: 1907-1913.
  96. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006;55:885-91.
  97. Lourida ES, Papathanasiou AI, MD, Goudevenos JG, Tselepis AD. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2006;75:117-26.
  98. Gazi IF, Filippatos TD, Tsimihodimos V, Saougos VG, Liberopoulos EN, Mikhailidis DP, Tselepis AD, Elisaf M. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids. 2006;41:647-54.
  99. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, Drosos AA. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis; Effect of early treatment - a prospective, controlled study. Arthritis Res Ther. 2006; 8:R82.
  100. Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasilliou EC, Tselepis AD. Long-term treatment with Erythropoietin increases the serum levels of high-density lipoprotein in patients with chronic kidney disease. Am J Kidney Dis. 2006; 48:242-9.
  101. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006 ;48:752-60.
  102. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated Phospholipase A2 in Atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2094-2099.
  103. Beaufils C, Alexopoulos C, Petraki MP, Tselepis AD, Coudevylle N, Sakarellos-Daitsiotis M, Sakarellos C, Cung MT. Conformational study of new amphipathic alpha-helical peptide models of apoA-I as potential atheroprotective agents. Biopolymers. 2007;88:362-72.
  104. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27: 2236-2243.
  105. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch. Med. Res. 2007;38:403-410.
  106. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007;193:428-37.
  107. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007 ;30:323-6.
  108. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23:1169-76.
  109. Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007;29:1403-14.
  110. Papathanasiou A, Goudevenos J, Tselepis AD. Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. Hellenic J Cardiol. 2007;48:352-63.
  111. Lourida ES, Georgiadis AN, Papavasiliou EC, Papathanasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res Ther. 2007;9:R19.
  112. Tsimihodimos V, Gazi I, Kostara C, Tselepis AD, Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids. 2007; 42: 403-9.
  113. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007; 7: 53-72.
  114. Rizos EC, Spyrou A, Liberopoulos EN, Papavasiliou EC, Saougos V, Tselepis AD, Elisaf M. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J. 2007; 1: 22-6.
  115. Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, Tselepis AD, Katsilambros N. High postprandial triglyceridaemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res. 2007;48:218-25.
  116. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab. 2008 ;10: 476-83.
  117. Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis. 2008; 196: 289-97.
  118. Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, Elisaf MS. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol. 2008; 578: 249-52.
  119. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis. 2008; 18: 477-82.
  120. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother. 2008; 9: 3151-8.
  121. Koloka V, Christofidou ED, Vaxevanelis S, Dimitriou AA, Tsikaris V, Tselepis AD, Panou-Pomonis E, Sakarellos-Daitsiotis M, Tsoukatos DC. A palmitoylated peptide, derived from the acidic carboxyl-terminal segment of the integrin alphaIIb cytoplasmic domain, inhibits platelet activation. Platelets. 2008; 19: 502-11.
  122. Lekakis J, Bisti S, Tsougos E, Papathanassiou A, Dagres N, Ikonomidis I, Soteriadou E, Tselepis AD, Goudevenos J, Kremastinos DT. Platelet glycoprotein IIb HPA-3 polymorphism and acute coronary syndromes. Int J Cardiol. 2008 ;127:46-50.
  123. Florentin M, Liberopoulos EN, Filippatos TD, Kostara C, Tselepis A, Mikhailidis DP, Elisaf M. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother. 2008; 9: 2741-50.
  124. Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, Drosos AA. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum. 2008;38:13-9.
  125. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008; 24: 1919-29.
  126. Stanica RM, Benaki D, Rodis FI, Mikros E, Tsoukatos D, Tselepis A, Tsikaris V. Structure-activity relationships of alphaIIb 313-320 derived peptide inhibitors of human platelet aggregation. J Pept Sci. 2008; 14: 1195-202.
  127. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother. 2008; 9: 1829-37.
  128. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, Kourakli A, Adamopoulos S, Tselepis AD, Grapsas N, Siablis D, Zoumbos NC, Alexopoulos D. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis. 2008;198:448-57.
  129. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol. 2008; 590: 327-32.
  130. Papathanasiou AI, Goudevenos JA, Mikhailidis DP, Tselepis AD. Acute and long-term antiplatelet therapy. Drugs Today (Barc). 2008; 44: 331-52.
  131. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest. 2008; 38: 71-2.
  132. Nakou E, Filippatos TD, Liberopoulos EN, Tselepis AD, Kiortsis DN, Mikhailidis DP, Elisaf MS. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother. 2008; 9: 1629-39.
  133. Gazi IF, Milionis HJ, Filippatos TD, Tsimihodimos V, Kostapanos MS, Doumas M, Tselepis AD, Elisaf M. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev. 2008;24:223-30.
  134. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS. Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lipids. 2009 ;44:9-16.
  135. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther. 2009; 14: 5-13.
  136. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A(2) in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009; 1791: 327-38.
  137. Tsouli SG, Xydis V, Argyropoulou MI, Tselepis AD, Elisaf M, Kiortsis DN. Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: An ultrasonographic study. Atherosclerosis. 2009; 205: 151-5.
  138. Papamichael ND, Stathopoulou EM, Roussa VD, Tsironis LD, Kotsia AP, Stanica RM, Mousis V, Tsikaris V, Katsouras CS, Tselepis AD, Michalis LK. Effect of a synthetic peptide corresponding to residues 313-320 of the {alpha}IIb subunit of the human platelet integrin {alpha}IIb{beta}3 on carotid artery thrombosis in rabbits. J Pharmacol Exp Ther. 2009; 329: 634-40.
  139. Petraki MP, Mantani PT, Tselepis AD. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides. Curr Pharm Des. 2009; 15: 3146-66.
  140. Katsoura MH, Polydera AC, Tsironis LD, Petraki MP, Tselepis AD, Stamatis H. Efficient enzymatic preparation of hydroxycinnamates in ionic liquids enhances their antioxidant effect on lipoproteins oxidative modification. New Biotechnology. 2009; 26: 83-91.
  141. Dimitriou AA, Stathopoulos P, Mitsios JV, Sakarellos-Daitsiotis M, Goudevenos J, Tsikaris V, Tselepis AD. Inhibition of platelet activation by peptide analogs of the beta(3)-intracellular domain of platelet integrin alpha(IIb)beta(3) conjugated to the cell-penetrating peptide Tat(48-60). Platelets. 2009; 20: 539-47.
  142. Tsimihodimos V, Gazi I, Filippatos T, Kostapanos M, Lagos K, Kostara C, Tellis CC, Elisaf M, Tselepis AD. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2009; 208: 506-11.
  143. Papathanasiou A, Goudevenos J, Tselepis AD. Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact. Curr Pharm Des. 2009; 15: 1085-94.
  144. Tselepis AD, Panagiotakos DB, Pitsavos C, Tellis CC, Chrysohoou C, Stefanadis C. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis. 2009; 206: 303-8.
  145. Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M, Liberopoulos EN. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res. 2009; 50: 2532-9.
  146. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol. 2009; 23: 595-600.
  147. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or ezetimibe, on Plasma Adipokine Levels: A Pilot Study. Angiology. 2010; 61: 365-71.
  148. Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010; 8: 820-30.
  149. Markakis KP, Koropouli MK, Grammenou-Savvoglou S, van Winden EC, Dimitriou AA, Demopoulos CA, Tselepis AD, Kotsifaki EE. Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages. J Lipid Res. 2010; 51: 2191-201.
  150. Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des. 2010; 16: 3808-14.
  151. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol. 2010; 28: 880-3.
  152. Oskolkova OV, Afonyushkin T, Preinerstorfer B, Bicker W, von Schlieffen E, Hainzl E, Demyanets S, Schabbauer G, Lindner W, Tselepis AD, Wojta J, Binder BR, Bochkov VN. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol. 2010; 185: 7706-12.
  153. Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A, Alexopoulos DC. Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia. J Lipid Res. 2010; 51: 3331-41.
  154. Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, Liberopoulos EN, Elisaf M. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis. 2010; 212: 607-13.
  155. Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. 2011; 12: 2605-11.
  156. Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS, Tselepis AD. Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. Lipids. 2011; 46: 953-60.
  157. Hahalis G, Kalogeropoulos A, Terzis G, Tselepis AD, Kourakli A, Mylona P, Grapsas N, Alexopoulos D. Premature atherosclerosis in non-transfusion-dependent β-thalassemia intermedia. Cardiology. 2011; 118: 159-63.
  158. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011; 9: 531-2.
  159. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011; 9: 533-71.
  160. Tsimogiannis KE, Telis K, Tselepis A, Pappas-Gogos GK, Tsimoyiannis EC, Basdanis G. Α-defensin expression of inflammatory response in open and laparoscopic colectomy for colorectal cancer. World J Surg. 2011; 35: 1911-7.
  161. Tselepis AD, Gerotziafas G, Andrikopoulos G, Anninos H, Vardas P. Mechanisms of platelet activation and modification of response to antiplatelet agents. Hellenic J Cardiol. 2011; 52: 128-40.
  162. Kostapanos MS, Spyrou AT, Tellis CC, Gazi IF, Tselepis AD, Elisaf M, Liberopoulos EN. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids. 2011; 46 :341-8.
  163. Rizos CV, Liberopoulos EN, Tellis CC, Florentin M, Elisaf MS, Tselepis AD. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂. Metab Syndr Relat Disord. 2011; 9: 217-23.
  164. Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. 2011; 46: 521-8.
  165. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011; 27: 685-92.
  166. Kalantzi KI, Dimitriou AA, Milionis HJ, Goudevenos IA, Tselepis AD. Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost. 2011; 9: 875-8.
  167. Roussa VD, Stathopoulou EM, Papamichael ND, Englezopoulos CV, Rousouli KI, Trypou P, Moussis V, Tellis CC, Katsouras CS, Tsikaris V, Tselepis AD, Michalis LK. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits. Platelets. 2011; 22: 361-70.
  168. Tselepis AD, Tsoumani ME, Kalantzi KI, Dimitriou AA, Tellis CC, Goudevenos IA. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J Thromb Haemost. 2011; 9: 2371-8.
  169. Tselepis AD, Rizzo M, Goudevenos IA. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). Curr Pharm Des. 2011; 17: 3656-61.
  170. Derdemezis CS, Kiortsis DN, Tsimihodimos V, Petraki MP, Vezyraki P, Elisaf MS, Tselepis AD. Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. Biochem Res Int. 2011; 2011:285618.
  171. Darvari MI, Petraki MP, Tellis C, Harilogis K, Tselepis AD, Sakarellos-Daitsiotis M. Apolipoprotein A-I peptide models as probes to formulate potential inhibitors of the low-density lipoprotein oxidation. J Pept Sci. 2011; 17: 720-5.
  172. Verouti SN, Fragopoulou E, Karantonis HC, Dimitriou AA, Tselepis AD, Antonopoulou S, Nomikos T, Demopoulos CA. PAF effects on MCP-1 and IL-6 secretion in U-937 monocytes in comparison with oxLDL and IL-1β effects. Atherosclerosis. 2011; 219: 519-25.
  173. Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets. 2012; 23: 121-31.
  174. Rallidis LS, Tellis CC, Lekakis J, Rizos I, Varounis C, Charalampopoulos A, Zolindaki M, Dagres N, Anastasiou-Nana M, Tselepis AD. Lipoprotein-associated phospholipase A2 (Lp-PLA2) bound on high density lipoprotein is associated with lower risk of cardiac death in stable coronary artery disease patients: a three year follow-up. J Am Coll Cardiol. 2012; 60: 2053-60.
  175. Tsimogiannis KE, Tellis CC, Tselepis AD, Pappas-Gogos G, Bakola MS, Tsimoyiannis EC, Simopoulos CE, Pitiakoudis M. α-Defensins and hsCRP levels in inflammatory response of standard and laparoendoscopic single-site cholecystectomy. Surg Endosc. 2012; 26: 627-31.
  176. Moutzouri E, Tellis CC, Rousouli K, Liberopoulos EN, Milionis HJ, Elisaf MS, Tselepis AD. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012; 225: 381-7.
  177. Stakos DA, Gatsiou A, Stamatelopoulos K, Tselepis AD, Stellos K. Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets. Platelets. 2012; In press.
  178. Constantinides A, Kerstens MN, Dikkeschei BD, van Pelt LJ, Tellis CC, Tselepis AD, Dullaart RP. Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium. Eur J Clin Invest. 2012; 42: 1235-43.
  179. Constantinides A, de Vries R, van Leeuwen JJ, Gautier T, van Pelt LJ, Tselepis AD, Lagrost L, Dullaart RP. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med. 2012; 23: 633-8.
  180. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. 2012; 66: 843-53.
  181. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones (Athens). 2012; 11: 178-88.
  182. Tzakos AG, Kontogianni VG, Tsoumani M, Kyriakou E, Hwa J, Rodrigues FA, Tselepis AD. Exploration of the antiplatelet activity profile of betulinic acid on human platelets. J Agric Food Chem. 2012; 60: 6977-83.
  183. Kalantzi KI, Tsoumani ME, Goudevenos IA, Tselepis AD. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol. 2012; 5: 319-36.
  184. Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, Tselepis AD, Chapman MJ, Tsimikas S. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res. 2012; 53: 1670-8.
  185. Tsoumani ME, Kalantzi KI, Goudevenos IA, Tselepis AD. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. Curr Vasc Pharmacol. 2012; 10: 539-49.
  186. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res. 2012; 44: 6-14.
  187. Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. Expert Opin Pharmacother. 2012; 13: 149-58.
  188. Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. Angiology. 2012; 63: 547-51.
  189. Tsimogiannis KE, Tellis CC, Tselepis AD, Pappas-Gogos GK, Tsimoyiannis EC, Basdanis G. Toll-like receptors in the inflammatory response during open and laparoscopic colectomy for colorectal cancer. Surg Endosc. 2012; 26: 330-6.
  190. Christou GA, Tellis CC, Elisaf MS, Tselepis AD, Kiortsis DN. The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. Angiology. 2012; 63: 67-75.
  191. Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis. 2013; 23: 330-6.
  192. Kei A, Liberopoulos E, Tellis C, Elisaf M, Tselepis A. Lipid-Modulating Treatments for Mixed Dyslipidemia Increase HDL-Associated Phospholipase A2 Activity with Differential Effects on HDL Subfractions. Lipids. 2013; In press.
  193. Tsoumani ME, Kalantzi KI, Goudevenos IA, Tselepis AD. Clopidogrel Generic Formulations in the Era of New Antiplatelets. A Systematic Review. Curr Vasc Pharmacol. 2013; In press.
  194. Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. Eur J Clin Invest. 2013; 43: 698-707.
  195. Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes. Lipids. 2013; 48: 547-55.
  196. Rizos CV, Liberopoulos EN, Tellis CC, Tselepis AD, Elisaf MS. The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels. Arch Med Sci. 2013; 9: 172-6.
  197. Pappas-Gogos G, Tellis C, Lasithiotakis K, Tselepis AD, Tsimogiannis K, Tsimoyiannis E, Chalkiadakis G, Chrysos E. Oxidative stress markers in laparoscopic versus open colectomy for cancer: a double-blind randomized study. Surg Endosc. 2013; 27: 2357-65.
  198. Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol. 2013; 42: 169-75.
  199. Moutzouri E, Tsimihodimos V, Tselepis AD. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Curr Pharm Des. 2013; 19: 3827-40.
  200. Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens. 2013; 27: 44-50.
  201. Tselepis AD. Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. Curr Med Res Opin. 2013 [Epub ahead of print].
  202. Tellis CC, Moutzouri E, Elisaf M, Wolfert RL, Tselepis AD. The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA2. J Lipid Res. 2013; 54: 3394-402.
  203. Rizos CV, Liberopoulos EN, Tellis K, Dinicolantonio JJ, Tselepis AD, Elisaf MS. Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARγ-Activating Capacity: Effects on High-Density Lipoprotein Subfractions and Associated Enzymes. Angiology. 2013. [Epub ahead of print].
  204. Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013; 231: 8-14.
  205. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Mol Diagn Ther. 2014; Jan 16. [Epub ahead of print].

 

Greek